Skip to main content
Log in

Autoantibody-Negative Autoimmune Hepatitis

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Autoimmune hepatitis has a variable clinical phenotype, and the absence of conventional autoantibodies does not preclude its diagnosis or need for treatment. The goals of this review are to describe the frequency and nature of autoantibody-negative autoimmune hepatitis, indicate its outcome after corticosteroid treatment, and increase awareness of the diagnosis in patients with unexplained acute and chronic hepatitis. The frequency of presumed autoantibody-negative autoimmune hepatitis in patients with acute and acute severe presentations is ≤7%, and its frequency in patients with chronic presentations is 1–34%. Patients with acute presentations can have normal serum γ-globulin levels, centrilobular zone 3 necrosis, and low pre-treatment international diagnostic scores. Liver tissue examination is essential for the diagnosis, and hepatic steatosis can be a co-morbid feature. The comprehensive international scoring system can support but never override the clinical diagnosis pre-treatment, and non-standard serological markers should be sought if the clinical diagnosis is uncertain or the diagnostic score is low. A 3-month treatment trial with corticosteroids should be considered in all patients, regardless of the serological findings, and improvements have occurred in 67–87% of cases. Autoantibody-negative autoimmune hepatitis may be associated with an autoantibody outside the conventional battery; it may have a signature autoantibody that is still undiscovered, or its characteristic autoantibodies may have been suppressed or have a delayed expression. The pathogenic mechanisms are presumed to be identical to those of classical disease. Autoantibody-negative autoimmune hepatitis is an infrequent but treatable disease that must be considered in unexplained acute and chronic hepatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.

    Article  PubMed  CAS  Google Scholar 

  2. Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol. 2007;1:129–143.

    Article  PubMed  CAS  Google Scholar 

  3. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.

    Article  PubMed  CAS  Google Scholar 

  4. Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:339–341, 344–338.

    Article  PubMed  CAS  Google Scholar 

  5. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161–167.

    Article  PubMed  CAS  Google Scholar 

  6. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540–1548.

    Article  PubMed  Google Scholar 

  7. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology. 2011;140:1472–1480.

    Article  PubMed  Google Scholar 

  8. Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421–3438.

    Article  PubMed  Google Scholar 

  9. Johnson PJ, McFarlane IG, McFarlane BM, Williams R. Auto-immune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional auto-antibodies. J Gastroenterol Hepatol. 1990;5:244–251.

    Article  PubMed  CAS  Google Scholar 

  10. Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2011;56:545–554.

    Article  PubMed  CAS  Google Scholar 

  11. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996;24:1068–1073.

    Article  PubMed  CAS  Google Scholar 

  12. Cançado EL, Abrantes-Lemos CP, Vilas-Boas LS, Novo NF, Carrilho FJ, Laudanna AA. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J Autoimmun. 2001;17:223–228.

    Article  PubMed  Google Scholar 

  13. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–264.

    Article  PubMed  CAS  Google Scholar 

  14. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41:677–683.

    Article  PubMed  Google Scholar 

  15. Chretien-Leprince P, Ballot E, Andre C, et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann N Y Acad Sci. 2005;1050:266–273.

    Article  PubMed  CAS  Google Scholar 

  16. Torres-Collado AX, Czaja AJ, Gelpí C. Anti-tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int. 2005;25:410–419.

    Article  PubMed  CAS  Google Scholar 

  17. Frenzel C, Herkel J, Lüth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol. 2006;101:2731–2736.

    Article  PubMed  CAS  Google Scholar 

  18. Granito A, Muratori L, Muratori P, et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol. 2006;59:280–284.

    Article  PubMed  CAS  Google Scholar 

  19. Guéguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol. 2006;26:495–505.

    Article  PubMed  CAS  Google Scholar 

  20. Aubert V, Pisler IG, Spertini F. Improved diagnoses of autoimmune hepatitis using an anti-actin ELISA. J Clin Lab Anal. 2008;22:340–345.

    Article  PubMed  Google Scholar 

  21. Hausdorf G, Roggenbuck D, Feist E, et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA—revival of a disease-activity marker in autoimmune hepatitis. Clin Chim Acta. 2009;408:19–24.

    Article  PubMed  CAS  Google Scholar 

  22. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.

    Article  PubMed  CAS  Google Scholar 

  23. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem. 2005;40:127–164.

    Article  PubMed  CAS  Google Scholar 

  24. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc. 1990;65:23–30.

    PubMed  CAS  Google Scholar 

  25. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993;104:1755–1761.

    PubMed  CAS  Google Scholar 

  26. Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol. 1998;28:78–83.

    Article  PubMed  CAS  Google Scholar 

  27. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52:2433–2437.

    Article  PubMed  CAS  Google Scholar 

  28. Potthoff A, Deterding K, Trautwein C, et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol. 2007;45:15–19.

    Article  PubMed  CAS  Google Scholar 

  29. Heringlake S, Schütte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol. 2009;47:417–423.

    Article  PubMed  CAS  Google Scholar 

  30. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Büschenfelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology. 1990;11:606–612.

    Article  PubMed  CAS  Google Scholar 

  31. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992;16:892–898.

    Article  PubMed  CAS  Google Scholar 

  32. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85–92.

    Article  PubMed  CAS  Google Scholar 

  33. Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 2008;23:1410–1414.

    Article  PubMed  Google Scholar 

  34. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci. 1986;31:705–711.

    Article  PubMed  CAS  Google Scholar 

  35. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993;105:1522–1528.

    Article  PubMed  CAS  Google Scholar 

  36. Nezu S, Tanaka A, Yasui H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2006;21:1448–1454.

    PubMed  CAS  Google Scholar 

  37. Mishima S, Omagari K, Ohba K, et al. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology. 2008;55:221–227.

    PubMed  CAS  Google Scholar 

  38. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:1047–1053.

    Article  PubMed  Google Scholar 

  39. O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008;48:550–556.

    Article  PubMed  Google Scholar 

  40. Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol. 2008;43:951–958.

    Article  PubMed  Google Scholar 

  41. Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52:1233–1235.

    PubMed  Google Scholar 

  42. Fujiwara K, Yasui S, Tawada A, Fukuda Y, Nakano M, Yokosuka O. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. Liver Int. 2011;31:1013–1020.

    Article  PubMed  CAS  Google Scholar 

  43. Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res. 2011;41:133–141.

    Article  PubMed  Google Scholar 

  44. Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47:664–670.

    Article  PubMed  CAS  Google Scholar 

  45. Hiramatsu A, Takahashi S, Aikata H, et al. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J Gastroenterol Hepatol. 2008;23:1216–1222.

    Article  PubMed  Google Scholar 

  46. Mehendiratta V, Mitroo P, Bombonati A, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2009;7:98–103.

    Article  PubMed  Google Scholar 

  47. Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. Acta Med Okayama. 2008;62:217–226.

    PubMed  Google Scholar 

  48. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646–652.

    Article  PubMed  CAS  Google Scholar 

  49. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816–823.

    Article  PubMed  CAS  Google Scholar 

  50. Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149–2155.

    Article  PubMed  CAS  Google Scholar 

  51. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824–1832.

    PubMed  CAS  Google Scholar 

  52. Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52:1233–1235.

    PubMed  Google Scholar 

  53. Czaja AJ, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci. 1996;41:305–314.

    Article  PubMed  CAS  Google Scholar 

  54. Czaja AJ. Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. Dig Dis Sci. 1998;43:1725–1731.

    Article  PubMed  CAS  Google Scholar 

  55. Brandhagen DJ, Fairbanks VF, Batts KP, Thibodeau SN. Update on hereditary hemochromatosis and the HFE gene. Mayo Clin Proc. 1999;74:917–921.

    Article  PubMed  CAS  Google Scholar 

  56. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet. 1998;352:26–29.

    Article  PubMed  CAS  Google Scholar 

  57. Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology. 2002;122:881–888.

    Article  PubMed  Google Scholar 

  58. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol. 2004;2:107–112.

    Article  PubMed  Google Scholar 

  59. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263–270.

    Article  PubMed  Google Scholar 

  60. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631.

    Article  PubMed  Google Scholar 

  61. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5:898–907.

    Article  PubMed  Google Scholar 

  62. Powell EE, Jonsson JR, Clouston AD. Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis. 2010;28:186–191.

    Article  PubMed  Google Scholar 

  63. Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8:346–352.

    PubMed  Google Scholar 

  64. Akbar HO. Cryptogenic or autoimmune hepatitis. Saudi J Gastroenterol. 2002;8:99–101.

    PubMed  Google Scholar 

  65. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.

    Article  PubMed  Google Scholar 

  66. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269–291.

    Article  PubMed  CAS  Google Scholar 

  67. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.

    PubMed  CAS  Google Scholar 

  68. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876–883.

    Article  PubMed  CAS  Google Scholar 

  69. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990;30:358–363.

    PubMed  CAS  Google Scholar 

  70. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000;47:63–83.

    Article  PubMed  CAS  Google Scholar 

  71. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448–453.

    PubMed  CAS  Google Scholar 

  72. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102:1005–1012.

    Article  PubMed  CAS  Google Scholar 

  73. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–1206.

    Article  PubMed  CAS  Google Scholar 

  74. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215–221.

    Article  PubMed  CAS  Google Scholar 

  75. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999;30:131–141.

    Article  PubMed  CAS  Google Scholar 

  76. Cattan P, Berney T, Conti F, et al. Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int. 2002;15:34–38.

    Article  PubMed  Google Scholar 

  77. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145–155.

    Article  PubMed  CAS  Google Scholar 

  78. Núñez-Martínez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. Transplant Proc. 2003;35:1857–1858.

    Article  PubMed  Google Scholar 

  79. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004;18:62–69.

    Article  PubMed  Google Scholar 

  80. Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc. 2007;39:1166–1170.

    Article  PubMed  CAS  Google Scholar 

  81. Schramm C, Bubenheim M, Adam R, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl. 2010;16:461–469.

    PubMed  Google Scholar 

  82. Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008;14:1281–1286.

    Article  PubMed  Google Scholar 

  83. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis. 2002;22:379–386.

    Article  PubMed  Google Scholar 

  84. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis. 2009;29:286–296.

    Article  PubMed  Google Scholar 

  85. Duclos-Vallée JC, Yilmaz F, Johanet C, et al. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transplant. 2005;19:591–599.

    Article  PubMed  Google Scholar 

  86. Charlton MR, Kondo M, Roberts SK, Steers JL, Krom RA, Wiesner RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997;3:359–364.

    Article  PubMed  CAS  Google Scholar 

  87. Ku NO, Gish R, Wright TL, Omary MB. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med. 2001;344:1580–1587.

    Article  PubMed  CAS  Google Scholar 

  88. Syn WK, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl. 2007;13:984–989.

    Article  PubMed  Google Scholar 

  89. Sanjeevi A, Lyden E, Sunderman B, Weseman R, Ashwathnarayan R, Mukherjee S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc. 2003;35:2977–2980.

    Article  PubMed  CAS  Google Scholar 

  90. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transplant. 2010;16:431–439.

    Google Scholar 

  91. Heneghan MA, Zolfino T, Muiesan P, et al. An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2003;9:921–928.

    Article  PubMed  Google Scholar 

  92. McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother. 1999;53:255–263.

    Article  PubMed  CAS  Google Scholar 

  93. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.

    Article  PubMed  CAS  Google Scholar 

  94. Lapierre P, Béland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res. 2007;149:107–113.

    Article  PubMed  CAS  Google Scholar 

  95. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol. 2008;14:3306–3312.

    Article  PubMed  CAS  Google Scholar 

  96. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144–2161.

    Article  PubMed  CAS  Google Scholar 

  97. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.

    Article  PubMed  CAS  Google Scholar 

  98. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998;42:721–726.

    Article  PubMed  CAS  Google Scholar 

  99. Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med. 2002;13:293–303.

    Article  PubMed  CAS  Google Scholar 

  100. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413–419.

    Article  PubMed  Google Scholar 

  101. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol. 1999;31:635–640.

    Article  PubMed  CAS  Google Scholar 

  102. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475–483.

    Article  PubMed  CAS  Google Scholar 

  103. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci. 1996;41:1733–1740.

    Article  PubMed  CAS  Google Scholar 

  104. McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol. 1986;3:196–205.

    Article  PubMed  CAS  Google Scholar 

  105. Meyer zum Büschenfelde KH, Treichel U, Löhr H, Fleischer B, Poralla T. Human asialoglycoprotein receptor as an autoantigen in chronic hepatitis. Immunol Res. 1991;10:497–502.

    Article  PubMed  Google Scholar 

  106. Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Büschenfelde KH, Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol. 1993;19:55–63.

    Article  PubMed  CAS  Google Scholar 

  107. Dejica D, Treichel U, Pár A, Chira O, Meyer zum Büschenfelde KH. Anti asialoglycoprotein receptor antibodies and soluble interleukin-2 receptor levels as marker for inflammation in autoimmune hepatitis. Z Gastroenterol. 1997;35:15–21.

    PubMed  CAS  Google Scholar 

  108. Yoshioka M, Mizuno M, Morisue Y, et al. Anti-asialoglycoprotein receptor autoantibodies, detected by a capture-immunoassay, are associated with autoimmune liver diseases. Acta Med Okayama. 2002;56:99–105.

    PubMed  CAS  Google Scholar 

  109. Hilgard P, Schreiter T, Stockert RJ, Gerken G, Treichel U. Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis. Hepatology. 2004;39:1398–1407.

    Article  PubMed  CAS  Google Scholar 

  110. Husa P, Chalupa P, Stroblová H, Husová L, Slesinger P, Zajíc J. Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients. Acta Virol. 2001;45:7–11.

    PubMed  CAS  Google Scholar 

  111. Sasaki M, Yamauchi K, Tokushige K, et al. Clinical significance of autoantibody to hepatocyte membrane antigen in type 1 autoimmune hepatitis. Am J Gastroenterol. 2001;96:846–851.

    Article  PubMed  CAS  Google Scholar 

  112. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet. 1984;2:954–956.

    Article  PubMed  CAS  Google Scholar 

  113. Hajoui O, Martin S, Alvarez F. Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies. Clin Exp Immunol. 1998;113:339–345.

    Article  PubMed  CAS  Google Scholar 

  114. Schreiter T, Liu C, Gerken G, Treichel U. Detection of circulating autoantibodies directed against the asialoglycoprotein receptor using recombinant receptor subunit H1. J Immunol Methods. 2005;301:1–10.

    Article  PubMed  CAS  Google Scholar 

  115. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1993;17:411–417.

    Article  PubMed  CAS  Google Scholar 

  116. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology. 1995;108:1159–1166.

    Article  PubMed  CAS  Google Scholar 

  117. Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol. 1996;24:581–586.

    Article  PubMed  CAS  Google Scholar 

  118. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology. 1997;25:1105–1107.

    Article  PubMed  CAS  Google Scholar 

  119. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol. 2003;37:315–329.

    Article  PubMed  Google Scholar 

  120. De Riva V, Celadin M, Pittoni M, Plebani M, Angeli P. What is behind the presence of anti-neutrophil cytoplasmatic antibodies in chronic liver disease? Liver Int. 2009;29:865–870.

    Article  PubMed  Google Scholar 

  121. Terjung B, Spengler U, Sauerbruch T, Worman HJ. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000;119:310–322.

    Article  PubMed  CAS  Google Scholar 

  122. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a “leaky gut”? Clin Rev Allergy Immunol. 2009;36:40–51.

    Article  PubMed  CAS  Google Scholar 

  123. Sir JU, Kim TY. Is ANCA really related to chronic liver disease? Liver Int. 2010;30:157–158; author reply 158–159.

    Article  PubMed  Google Scholar 

  124. Dalekos GN, Tsianos EV. Anti-neutrophil antibodies in chronic viral hepatitis. J Hepatol. 1994;20:561.

    Article  PubMed  CAS  Google Scholar 

  125. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643–649.

    Article  PubMed  CAS  Google Scholar 

  126. Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology. 2001;34:494–501.

    Article  PubMed  CAS  Google Scholar 

  127. Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988;8:1662–1666.

    Article  PubMed  CAS  Google Scholar 

  128. Lenzi M, Manotti P, Muratori L, et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut. 1995;36:749–754.

    Article  PubMed  CAS  Google Scholar 

  129. Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology. 1995;21:58–62.

    PubMed  CAS  Google Scholar 

  130. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity. 2004;37:195–201.

    Article  PubMed  CAS  Google Scholar 

  131. Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet. 1994;344:578–581.

    Article  PubMed  CAS  Google Scholar 

  132. Durazzo M, Philipp T, Van Pelt FN, et al. Heterogeneity of liver–kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology. 1995;108:455–462.

    Article  PubMed  CAS  Google Scholar 

  133. Strassburg CP, Obermayer-Straub P, Alex B, et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology. 1996;111:1576–1586.

    Article  PubMed  CAS  Google Scholar 

  134. Csepregi A, Nemesánszky E, Luettig B, Obermayer-Straub P, Manns MP. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol. 2001;96:910–911.

    Article  PubMed  CAS  Google Scholar 

  135. Obermayer-Straub P, Manns MP. Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep. 1996;23:235–242.

    Article  PubMed  CAS  Google Scholar 

  136. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate–glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997;26:1054–1066.

    Article  PubMed  CAS  Google Scholar 

  137. Fusconi M, Cassani F, Zauli D, et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods. 1990;130:1–8.

    Article  PubMed  CAS  Google Scholar 

  138. Jaskowski TD, Konnick EQ, Ashwood ER, Litwin CM, Hill HR. Prevalence of IgG autoantibody against F-actin in patients suspected of having autoimmune or acute viral hepatitis. J Clin Lab Anal. 2007;21:249–253.

    Article  PubMed  CAS  Google Scholar 

  139. Martinez-Neira R, dos Remedios CG, Mackay IR. An actin-myosin functional assay for analysis of smooth muscle (anti-microfilament) autoantibodies in human plasma. J Immunol Methods. 2008;338:63–66.

    Article  PubMed  CAS  Google Scholar 

  140. Soares A, Cunha R, Rodrigues F, Ribeiro H. Smooth muscle autoantibodies with F-actin specificity. Autoimmun Rev. 2009;8:713–716.

    Article  PubMed  CAS  Google Scholar 

  141. Villalta D, Bizzaro N, Da Re M, Tozzoli R, Komorowski L, Tonutti E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity. 2008;41:105–110.

    Article  PubMed  CAS  Google Scholar 

  142. Zamanou A, Samiotaki M, Panayotou G, Margaritis L, Lymberi P. Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease. J Autoimmun. 2003;20:333–344.

    Article  PubMed  CAS  Google Scholar 

  143. Lidman K, Biberfeld G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol. 1976;24:266–272.

    PubMed  CAS  Google Scholar 

  144. Oikonomou KG, Zachou K, Dalekos GN. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev. 2011;10:389–396.

    Article  PubMed  CAS  Google Scholar 

  145. Renaudineau Y, Dalekos GN, Guéguen P, Zachou K, Youinou P. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol. 2008;34:321–325.

    Article  PubMed  CAS  Google Scholar 

  146. Volta U. Liver dysfunction in celiac disease. Minerva Med. 2008;99:619–629.

    PubMed  CAS  Google Scholar 

  147. Mackay IR, Larkin L, Burnet FM. Failure of autoimmune antibody to react with antigen prepared from the individual’s own tissues. Lancet. 1957;273:122–123.

    Article  PubMed  CAS  Google Scholar 

  148. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet. 1959;1:65–69.

    Article  PubMed  CAS  Google Scholar 

  149. Hopf U, Meyer zum Büschenfelde KH, Arnold W. Detection of a liver–membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med. 1976;294:578–582.

    Article  PubMed  CAS  Google Scholar 

  150. Frazer IH, Kronborg IJ, Mackay IR. Antibodies to liver membrane antigens in chronic active hepatitis (CAH). II. Specificity for autoimmune CAH. Clin Exper Immunol. 1983;54:213–218.

    CAS  Google Scholar 

  151. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26:567–572.

    Article  PubMed  CAS  Google Scholar 

  152. Czaja AJ, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol. 1995;23:32–38.

    Article  PubMed  CAS  Google Scholar 

  153. Chen M, Shirai M, Czaja AJ, et al. Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:483–489.

    Article  PubMed  CAS  Google Scholar 

  154. Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I. J Gastroenterol Hepatol. 2000;15:1176–1182.

    Article  PubMed  CAS  Google Scholar 

  155. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci. 2003;48:1658–1664.

    Article  PubMed  CAS  Google Scholar 

  156. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology. 1994;107:200–207.

    PubMed  CAS  Google Scholar 

  157. Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol. 1979;38:621–628.

    PubMed  CAS  Google Scholar 

  158. Fusconi M, Vannini A, Dall’Aglio AC, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2005;22:951–955.

    Article  PubMed  CAS  Google Scholar 

  159. Montano-Loza A, Czaja AJ, Carpenter HA, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity. 2006;39:341–348.

    Article  PubMed  CAS  Google Scholar 

  160. Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol. 1998;93:1334–1339.

    Article  PubMed  CAS  Google Scholar 

  161. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132:473–476.

    Article  PubMed  CAS  Google Scholar 

  162. Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig Dis Sci. 2004;49:611–618.

    Article  PubMed  CAS  Google Scholar 

  163. Parveen S, Morshed SA, Arima K, et al. Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci. 1998;43:1322–1331.

    Article  PubMed  CAS  Google Scholar 

  164. Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol. 2002;169:4889–4896.

    PubMed  Google Scholar 

  165. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology. 2004;39:1066–1074.

    Article  PubMed  CAS  Google Scholar 

  166. Lapierre P, Béland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun. 2006;26:82–89.

    Article  PubMed  CAS  Google Scholar 

  167. Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409–1422.

    Article  PubMed  CAS  Google Scholar 

  168. Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2010;4:429–443.

    Article  PubMed  CAS  Google Scholar 

  169. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224–1231.

    Article  PubMed  CAS  Google Scholar 

  170. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2007;53:43–78.

    PubMed  CAS  Google Scholar 

  171. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010;34:7–14.

    Article  PubMed  CAS  Google Scholar 

  172. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31–37.

    Article  PubMed  CAS  Google Scholar 

  173. Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63–71.

    Article  PubMed  CAS  Google Scholar 

  174. Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484–4491.

    PubMed  CAS  Google Scholar 

  175. Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581–591.

    Article  PubMed  CAS  Google Scholar 

  176. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103:264–274.

    PubMed  CAS  Google Scholar 

  177. al-Wabel A, al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol. 1993;92:902–908.

    Article  PubMed  CAS  Google Scholar 

  178. Schlaak JF, Löhr H, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin Exp Immunol. 1993;94:168–173.

    Article  PubMed  CAS  Google Scholar 

  179. Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 1995;20:23–27.

    Article  PubMed  CAS  Google Scholar 

  180. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851–856.

    Article  PubMed  CAS  Google Scholar 

  181. Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645–652.

    Article  PubMed  CAS  Google Scholar 

  182. Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci. 2000;45:1028–1035.

    Article  PubMed  CAS  Google Scholar 

  183. Chen W, Perruche S, Li J. CD4+CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14:2245–2249.

    Article  PubMed  CAS  Google Scholar 

  184. Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z Gastroenterol. 2007;45:63–70.

    Article  PubMed  CAS  Google Scholar 

  185. Löhr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 1991;84:297–302.

    Article  PubMed  Google Scholar 

  186. Löhr H, Treichel U, Poralla T, Manns M, Meyer zum Büschenfelde KH. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol. 1992;88:45–49.

    Article  PubMed  Google Scholar 

  187. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J. 1998;12:1255–1265.

    PubMed  CAS  Google Scholar 

  188. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med. 1999;341:2068–2074.

    Article  PubMed  CAS  Google Scholar 

  189. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225–232.

    Article  PubMed  CAS  Google Scholar 

  190. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727–737.

    Article  PubMed  Google Scholar 

  191. Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2006;2:33–48.

    Article  PubMed  CAS  Google Scholar 

  192. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388.

    Article  PubMed  CAS  Google Scholar 

  193. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658–664.

    Article  PubMed  CAS  Google Scholar 

  194. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol. 1997;92:2197–2200.

    PubMed  CAS  Google Scholar 

  195. Bittencourt PL, Goldberg AC, Cançado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906–1913.

    Article  PubMed  CAS  Google Scholar 

  196. Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol. 2006;45:844–850.

    Article  PubMed  CAS  Google Scholar 

  197. Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci. 2007;52:179–184.

    Article  PubMed  Google Scholar 

  198. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953–955.

    Article  PubMed  Google Scholar 

  199. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–976.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

This review did not receive financial support from a funding agency or institution, and Albert J. Czaja, MD, has no conflict of interests to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Albert J. Czaja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czaja, A.J. Autoantibody-Negative Autoimmune Hepatitis. Dig Dis Sci 57, 610–624 (2012). https://doi.org/10.1007/s10620-011-2017-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-011-2017-z

Keywords

Navigation